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Metastatic breast cancer (MBC) remains a challenging disease to treat with only a small
minority of patients achieving long-term survival. Although great strides have been made
in the fight against breast cancer, international consensus to the approach to treat the dis-
ease is lacking. Over the past few decades, the introduction of several new agents, includ-
ing biologically-targeted agents, have impacted disease control as well as survival, albeit
modestly. Despite these advances, treatment for the majority of breast cancer remains
empirically based, especially in the approach to HER2-negative, endocrine non-sensitive
disease. Taxane- and anthracycline-containing regimens continue to be a mainstay of
MBC therapy; however, increasing use of these agents in the adjuvant and neoadjuvant set-
tings provides a challenge for the treating oncologist. As such, this review will focus on
state of the art therapy for patients with endocrine non-sensitive, HER2-negative MBC,
highlighting recent advances offering new treatment paradigms.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
Breast cancer is a diverse disease comprising many biological
subtypes. Gene expression studies using DNA microarrays
have identified five main subtypes: luminal A, luminal B,
HER-2 positive, basal-like and normal breast-like. These sub-
types differ markedly in prognosis and in the repertoire of
therapeutic target they express. Disease characteristics, such
as hormone receptor status, human epidermal growth factor
receptor-2 (HER2) status, site and extent of metastatic spread,
disease-free interval and type of prior adjuvant therapy, as
well as patient characteristics including age, performance
status, co-morbidities and patient preferences all play key
roles in determining how best to treat an individual patient
with metastatic breast cancer (MBC) (Fig. 1). Unfortunately,
there are only a few accepted predictive factors associated
with treatment benefit, i.e., hormone receptor status and
HER2 status. Consequently, for patients with HER2-negativeer Ltd. All rights reserved
8.
tand hormone receptor-negative disease (basal-like subtype),
treatment decision-making can be complicated and requires
careful consideration of the reported literature. Choosing
the appropriate regimen for this group of advanced breast
cancer patients can be challenging, but important distinc-
tions in patient and tumour characteristics can help guide
treatment decisions (Table 1).1.1. Choosing the right chemotherapy regimen
As treatment in the metastatic setting is palliative, tolerability
and patients’ quality-of-life are major factors guiding treat-
ment decisions. Chemotherapy is currently the standard of
care for women with HER2-negative, endocrine non-sensitive
disease or for women with extensive visceral or life-threaten-
ing disease regardless of hormone receptor status. The ques-
tion of how to best administer chemotherapy, in combination
or as sequential single-agents, remains unanswered. Almost
assuredly, no single strategy is appropriate for all patients. In
general, however, administering agents simultaneously tends
to yield higher overall response rates (ORR), higher complete
.
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Fig. 1 – Factors to be considered in decision-making.
Table 1 – Choosing the right regimen for advanced breast
cancer
‘Friendly’ agent/regimen ‘Aggressive’ regimen
Slowly-progressing disease Rapidly progressing/life-threatening
disease
Any site provided limited
visceral involvement
Massive visceral involvement
Asymptomatic patient Symptomatic patient
Indication for
polychemotherapy
but frail
Fit
±Biological agents
E J C S U P P L E M E N T S 6 ( 2 0 0 8 ) 1 0 –1 5 11response rates (CRR), longer time-to-disease progression (TTP)
and in some trials, a modest improvement in overall survival
(OS); although, with the cost of increased toxicity. Sequential
delivery yields lower response rates and a shorter TTP but
avoids additive or overlapping toxicity, and may provide com-
parable OS relative to combination treatment.1–3
1.2. Taxane- and anthracycline-containing regimens
In addition to being a mainstay of therapy in the adjuvant and
neoadjuvant settings, anthracyclines are standards in chemo-
therapy regimens for MBC. In the pre-taxane era, randomised
trials in MBC demonstrated that anthracycline-containing
combination regimens reduced the risk of death when com-
pared with monotherapy and were superior to non-anthracy-
cline-containing combination regimens.4,5 Since their initial
clinical development in the treatment of breast cancer, the
taxanes, docetaxel and paclitaxel, have joined the anthracy-
clines as preferred cytotoxic agents for the treatment of meta-
static breast cancer, either as single agents or in combination.
As the taxanes and the anthracyclines are two of the most
active classes of agents in breast cancer, several trials have
compared standard anthracycline-based combinations with
taxane–anthracycline combinations in the first-line treatment
of MBC. Early trials evaluating paclitaxel in combination with
doxorubicin demonstrated high response rates of over 80%,
but with unexpectedly high rates of congestive heart failure
(CHF), approximating 18–20%.6,7 These cardiac effects have
been attributed to pharmacokinetic interactions between pac-
litaxel and both doxorubicin and itsmetabolite, doxorubicinol.
Several strategies to maintain efficacy and minimise cardio-
toxicity of the doxorubicin–paclitaxel combination have beeninvestigated, including extending the interval of time between
doxorubicin and paclitaxel administration, prolonging the
infusion duration of paclitaxel to 24 hours, limiting the cumu-
lative doxorubicin dose to 360 mg/m2, substituting docetaxel
for paclitaxel, and substituting epirubicin or novel forms of
doxorubicin, such as pegylated liposomal doxorubicin, for
standard doxorubicin.
Unlike paclitaxel, early trials of docetaxel have not shown
significant pharmacokinetic interactions with either doxoru-
bicin or epirubicin.8,9 Results of phase III trials investigating
the combination of docetaxel-based anthracycline combina-
tions as first-line therapy for MBC have been encouraging in
terms of ORR and TTP but have also been associated with
an increased toxicity. In addition, there has been a lack of
consistent survival benefit when compared with standard
anthracycline-based combination regimens.10–12
Based on inconsistent results from clinical trials utilising
single-agent and combination taxane therapy, including the
lack of a predictable survival benefit in most of these trials,
guidelines for the optimal use of taxanes in the first-line MBC
setting are lacking. A recently reported meta-analysis evalu-
ated individual patient data from relevant trials of taxanes,
either alone or combined with anthracyclines, in the first-line
treatment of MBC. The goal of this meta-analysis was to deter-
mine if a survival benefit could be shown in the overall popula-
tion or in a subset of patients with visceral metastases.13 Data
were collected for all of the 3953 patients randomised in the 11
trials included in this analysis; 3034 patients contributed to the
comparison of taxane–anthracycline combinations versus
non-taxane-containing anthracycline combination regimens
and 919 from trials comparing single-agent taxanes with sin-
gle-agent anthracyclines. The analysis demonstrated that
whilst progression-free survival (PFS) was significantly better
with single-agent anthracycline therapy when compared to
single-agent taxane therapy for the first-line treatment of
MBC, OS was similar in both groups. Taxane–anthracycline
combinations resulted in significantly better ORR but offered
only amarginal benefit in PFS and no benefit in OS when com-
pared with anthracycline combinations that did not contain a
taxane. In the visceral versus non-visceral disease analysis,
there was a slightly more pronounced effect favouring the
incorporation of taxanes. This meta-analysis failed to demon-
strate a gain in survival associatedwith the introduction of the
taxanes in the first-line treatment of MBC. However, it did
establish their contribution to provide an improved chance of
response, which may be important in subsets of patients.
The relationship of RR as a surrogate endpoint for survival
prolongation has not been firmly established.14–16
1.3. Incorporating targeted therapies in HER2-negative
disease
Recent strides in the clinical development of targeted biolog-
ical therapies offer new hope and an entirely new treatment
paradigm for patients with MBC as evidenced by the pivotal
practise changing anti-HER2 therapeutic, trastuzumab. Re-
cently, much excitement and research has been focused on
the development of agents that inhibit tumour angiogenesis.
Vascular endothelial growth factor (VEGF) and its receptors
are key regulators of the process of angiogenesis, which
12 E J C S U P P L E M E N T S 6 ( 2 0 0 8 ) 1 0 –1 5makes them desirable therapeutic targets. Bevacizumab, a
humanised monoclonal antibody directed against all iso-
forms of VEGF-A, is first in its class to be investigated in
MBC. Both preclinical and early clinical trials suggest bev-
acizumab has anti tumour activity as well as a favourable tox-
icity profile, with hypertension, proteinuria, thrombosis and
bleeding being the most commonly reported toxicities. These
toxicities are rarely therapy-limiting.17,18
In the first phase III trial of bevacizumab in MBC patients
who had received prior chemotherapy for metastatic disease,
the addition of bevacizumab to capecitabine demonstrated
better ORR compared with capecitabine alone, but no benefit
in PFS or OS.19 Although disappointing, the lack of benefit in
survival endpoints in this highly refractory population was
not surprising, as it has been shown that angiogenic pathways
become more numerous and redundant as breast cancer pro-
gresses. To test the hypothesis that anti-angiogenic agents
would prove superior in a less refractory patient population,
the Eastern Cooperative Oncology Group, led by Kathy Miller
and colleagues, evaluated the role of bevacizumab in combina-
tion with chemotherapy in chemo-naı¨ve MBC.20 In this trial
(ECOG2100), patients were randomised to paclitaxel (90 mg/
m2) on days 1, 8, and 15 every 4 weeks alone or in combination
with bevacizumab (10 mg/kg) on days 1 and 8. Patients with
HER2-positive diseasewere excluded unless they had received
prior trastuzumab or had a contraindication to trastuzumab
use. Previous treatment with a taxane in the adjuvant setting
was permitted if the disease-free interval was greater than 12
months. The primary end-point of the trial was PFS. The find-
ings from the most recently reported interim analysis demon-
strated a doubling of the ORR (29.9% versus 13.8%; p < 0.0001)
and a significantly prolonged PFS (11.4 months versus 6.11
months; HR 0.51, p < 0.0001) favouring the bevacizumab-con-
taining arm; OS data are premature and remain unreported.
Toxicity was manageable with small increases in grade 3
peripheral neuropathy and fatigue reported for the combina-
tion treatment. Approximately 15%of patients in the combina-
tion arm developed hypertension requiring medication; no
effect on cardiac functionwas noted. Thromboembolic events,
serious bleeding and grade 3 or 4 proteinuria were rarely re-
ported. In addition, there were no significant differences in
symptom burden or health-related quality-of-life (HRQL)
scores between the 2 treatment arms.21 Obtaining these re-
sults from the patients’ perspective provides reassurance that
the increase in PFS is not at the cost of impairments in HRQL.
Recently, investigators studied the combination of capecit-
abine (1000 mg/m2 twice daily on days 1–15; 28 doses) and
bevacizumab (15 mg/kg on day 1; repeated every 21 days until
progression) in a single-arm, 2-phase study, for the first-lineTable 2 – Capecitabine plus bevacizumab in first-line MBC
ITT (N = 109)
Median TTP, months (95% CI) 5.7 (4.9–8.4)
Median OS, months (95% CI) 16+ (12.9-NR)
ORR (CR + PR) 38%
CI, confidence interval; ER, oestrogen receptor; ITT, intent-to-treat; NR, no
to-progression.treatment of HER2-negative MBC.22 The trial met the primary
endpoint of TTP (90% power to test an improvement in the
TTP from 4 months, as reported previously for single-agent
capecitabine, to 5.6 months), reporting 5.7 months in the
intention-to-treat population. The combination produced an
ORR of 38% and median OS has not been reached but is in ex-
cess of 16 months. Of note, patients with ER-positive disease
did better than patients with ER-negative tumours (median
TTP 8.9 versus 4 months for patients with ER-positive and
ER-negative disease, respectively) (Table 2). These data are
provocative, and even with the limitation of the small number
of patients entered in the subgroup analysis, clearly ask for a
better definition of the patients most likely to benefit from
VEGF-directed therapies.
Lapatinib, an oral tyrosine kinase inhibitor with dual activ-
ity against both epidermal growth factor (EGFR) and HER2, has
demonstrated clinical activity for HER2-overexpressing ad-
vanced breast cancer.23 The role of this small molecule was
recently studied in women with either HER2-negative or
unknown MBC.24 Patients were randomly assigned to
receive either lapatinib (1500 mg once daily) and paclitaxel
(175 mg/m2) every 3 weeks or the same paclitaxel regimen
and placebo. Although the ORR was significantly higher in
the paclitaxel/lapatinib group compared with the paclitaxel/
placebo group (35.1% versus 25.3%, p = 0.008, respectively),
there was no difference in median duration of response (6.5
versus 6.2 months), median TTP (6.7 versus 5.3 months),
event-free survival (5.8 versus 5.2 months) or OS (22.8 versus
22.0 months). Approximately 15% of study participants on
blinded central review of archival tumour tissue had tumours
that overexpressed HER2. Retrospective analyses demon-
strated that combination therapy in these HER2-positive wo-
men produced a significantly better ORR, TTP, event-free
survival and a similar but non-significant trend for OS.
1.4. Maintenance therapy
In addition to lingering questions on how best to give chemo-
therapy as well as the optimal agent(s) to utilise, questions
also remain on the optimal duration of treatment. Most trials
that have attempted to answer this question have demon-
strated a benefit for TTP in continuing chemotherapy,
although not for survival. A meta-analysis of four of these tri-
als showed a modest survival advantage for women random-
ised to more cycles of chemotherapy.25 Two recently reported
trials, the MANTA and GEICAM 2001-01, have attempted to
address the role of maintenance therapy in MBC. In the MAN-
TA trial, no improvement in PFS was demonstrated from an
interim futility analysis in patients who were randomisedER-negative (n = 49) ER-positive (n = 51)
4 (3.0–4.9) 8.9 (7.5–13.6)
7.5 (5.6–16) 16.6+ (15.1-NR)
27% 47%
t reached; ORR, overall response rate; OS, overall survival; TTP, time-
Table 3 – Pegylated liposomal doxorubicin vs conven-
tional doxorubicin in high-risk MBC
N Cardiotoxicity
events
HR 95% CI
P65 years of age
PLD 78 0 N/Aa N/Aa
Doxorubicin 66 9
Prior adjuvant
chemotherapy
PLD 38 1 7.27 0.93–56.80
Doxorubicin 40 11
Cardiac risk factor
PLD 122 5 2.7 1.01–7.18
Doxorubicin 121 21
CI, confidence interval; HR, hazard ratio; PLD, pegylated liposomal
doxorubicin.
a HR cannot be determined as there are no events in the PLD
group.
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containing regimen and 8 courses of maintenance paclitaxel
versus no maintenance therapy.26 A number of variables con-
found these results, including small sample size due to pre-
mature closing of trial, the concurrent use of hormonal
therapy, the less optimal every-3-week schedule of paclitaxel,
as well as the fact that patients undergoing this aggressive
combination as upfront therapy are often younger and
healthier and have better outcomes than those who are trea-
ted with less aggressive treatment. Another reasonable expla-
nation for the lack of benefit seen in this trial is the more
effective administration of up-front therapy in this trial com-
pared with previously reported trials; nonetheless, the find-
ings suggest that women with MBC without progression
after adequate taxane-containing first-line chemotherapy do
not benefit from the administration of additional courses of
single-agent paclitaxel.
The GEICAM 2001-01 trial, on the other hand, did demon-
strate a statistically significant improvement in PFS for pa-
tients receiving pegylated liposomal doxorubicin (PLD)
(40 mg/m2 every 28 days for 6 cycles) as maintenance ther-
apy after the standard first-line MBC GEICAM regimen of
three cycles of doxorubicin 75 mg/m2 followed by three cy-
cles of docetaxel 100 mg/m2, both given every 21 days
(A!T).27 Maintenance endocrine therapy was not allowed
in the GEICAM trial. Despite the lack of strong data clearly
suggesting an advantage in introducing an endocrine ther-
apy as maintenance treatment at the completion of chemo-
therapy in endocrine-sensitive patients, this strategy is of
common use in clinical practise and can be considered a
limitation of the study. In any case, based on the results of
this trial, the GEICAM will consider PLD maintenance as a
standard approach to MBC in future clinical trials. Based
on the favourable tolerability of targeted agents in MBC, clin-
ical trials of these agents are also underway in the mainte-
nance setting.
1.5. The role of taxanes and anthracyclines in the
rechallenge setting
Despite adequate treatment for primary breast cancer, many
patients with apparently localised disease develop overt met-
astatic disease later in life. A challenge facing oncologists cur-
rently is the increasing number of patients who have been
exposed to both anthracyclines and taxanes in the adjuvant
setting. For these patients, treatment options include cyto-
toxic agents not utilised in the adjuvant setting or to rechal-
lenge the patient with an anthracycline and/or taxane;
either option with or without the addition of a targeted agent
such as bevacizumab or lapatinib.
Rechallenging a patient with a drug with proven efficacy
represents an opportunity to extend the role of active agents
in a patient with chemo-sensitive disease. Treatment-free
interval or time to recurrence is an important consideration
in this setting. If time to recurrence is greater than 12 months
to several years following adjuvant therapy, re-treatment with
prior active agents is worth considering. If progression or dis-
ease recurrence takes place in a relatively short time (e.g. <6–
12 months), the use of different classes of agents is generally
preferable.An international expert panel published evidenced-based
consensus guidelines suggesting that re-introduction of an
anthracycline more than 12 months after prior anthracycline
adjuvant or neo-adjuvant therapy is considered a viable op-
tion for first-line MBC treatment.28 The efficacy of anthracy-
cline rechallenge has been shown to be independent of
prior adjuvant therapy, including anthracyclines or CMF.29
An analysis of survival by prior adjuvant anthracycline use
from a phase III trial of doxorubicin–cyclophosphamide
(AC), docetaxel or alternating AC and docetaxel as first-line
chemotherapy for patients with MBC, found no difference in
OS whether or not patients had received prior anthracy-
clines.30 This adds to the body of literature indicating that
prior adjuvant use of anthracyclines does not adversely affect
outcomes with subsequent anthracycline use after relapse.
Despite the antitumour efficacy demonstrated by the
anthracyclines, particularly doxorubicin, their use is often
limited by the development of significant toxicity, mainly irre-
versible cardiotoxic effects that occur at increasing rates with
increasing cumulative doses of anthracyclines. It is also
important to note that the use of anthracyclines is generally
not recommended in settings where patients are at a greater
risk for the development of cardiac toxicity, i.e. older patients.
As such, novel dosage forms such as PLD have been devel-
oped in an attempt to modify the toxicity profile of conven-
tional doxorubicin whilst maintaining its efficacy. In a
randomised phase III trial in the first-line treatment of MBC,
PLD (50 mg/m2 every 4 weeks) and conventional doxorubicin
(60 mg/m2 every 3 weeks) had comparable efficacy in RR,
TTP and OS. PLD was associated with significantly less cardio-
toxicity, but mild to moderate hand–foot syndrome was ob-
served in the PLD group.31 In all subgroups analysed,
including patients at high risk for developing CHF and those
that received prior adjuvant anthracycline therapy, there
was a significantly decreased risk of developing cardiotoxicity
with PLD versus doxorubicin (Table 3). In fact, in a subgroup of
patients who received prior adjuvant anthracyclines, the risk
of cardiotoxicity was sevenfold higher with conventional
doxorubicin compared with the pegylated liposomal form.
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agents in the treatment of MBC, including paclitaxel, doce-
taxel, cyclophosphamide, gemcitabine, vinorelbine and trast-
uzumab. These trials demonstrated considerable activity and
tolerability of PLD in both the metastatic and locally advanced
settings, with a number of these trials including patients who
had received prior anthracyclines and/or taxanes. In a phase
II trial, PLD was evaluated in 79 women with MBC who had
been previously treated with conventional anthracyclines;
23% received prior adjuvant anthracyclines, 68% received
anthracyclines for metastatic disease, and 9% had received
anthracyclines in both the adjuvant andmetastatic settings.32
Patients were considered anthracycline-resistant if they had
disease progression on prior anthracyclines or within 6
months of adjuvant therapy. Not only did these patients fare
well overall, even with 30% having received P3 previous reg-
imens for MBC, no difference in clinical benefit rate
(ORR + SDP 24 weeks) was observed between patients who
had received PLD > 12months and thosewho received it with-
in 12 months of their last anthracycline therapy. Importantly,
no patients developed CHF or had a decrease in LVEF of great-
er than 15%, highlighting the safety as well as the clinical
activity of PLD in patients with previous anthracycline
exposure.
2. Conclusions
Despite advances in the treatment of MBC, only approxi-
mately 10% of patients are long-term survivors. Randomised
trials have been fundamental in helping to select treatment
strategies but the aim of MBC therapy is still primarily pallia-
tive and focused on prolonging survival and improving QoL
versus cure. Chemotherapy remains the gold standard for
patients with HER2-negative, ER- and PgR-negative breast
cancer. Extremely important would be the identification of
potential targets to customising treatment, looking not only
at the development of biological agents but also at a tailored
approach to chemotherapy. Ongoing studies are evaluating
the role of platinum compounds. The rationale is based on
the fact that roughly 80% of basal-like tumours present
BRCA-1 loss-of-function. The BRCA-associated genome sur-
veillance complex plays a key role in DNA repair. Therefore
patients whose tumours have DNA repair defective pathways
should be particularly sensitive to DNA-damaging agents
such as platinum compounds.
Poly (ADP-ribose) polymerase (PARP) is a DNA sensor that
signals the presence of DNA damage and facilitates DNA re-
pair. There are 17 PARP isoenzymes although PARP-1 seems
to play a critical role in signalling DNA damage and facilitat-
ing DNA repair. There are six different compounds inhibiting
PARP that are currently under evaluation in phase I–II clinical
trials. Interestingly enough, BRCA-1 protein deficient cells
seem to be highly sensitive to PARP inhibition compared to
wild-type cells. These pre-clinical data support the concept
that the combined use of DNA-damaging agents and PARP
inhibitors might be highly effective in triple-negative breast
cancer patients carrying BRCA-1 dysfunction. With a deeper
knowledge of the biology of basal-like tumours their ap-
proach will progress from an era of empirically based treat-
ment to an era of tailored therapies.Conflict of interest statement
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